Advanced PET Imaging in Prostate Cancer
Advanced PET Imaging in Prostate Cancer
Dr. Phillip Koo
Dr. Phillip J. Koo provides his thoughts on the use of advanced PET imaging in prostate cancer
Dr. Phillip Koo
Nuclear Medicine Physician
Banner MD Anderson Cancer Center
United States (US)
| 
5 min
|
2018
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Introducing the RADAR studies
Dr. Phillip J. Koo provides his thoughts on the use of advanced PET imaging in prostate cancer. He covers when to use these tools by examining the published data, specifically the RADAR 1 and 3 studies. The RADAR (radiographic assessments for detection of advanced recurrence) group, are a team of experts, including Dr Koo, who have published articles pertinent to prostate cancer imaging. The initial paper of RADAR 1 reviewed imaging guidelines with associated clinical validation studies for metastatic prostate cancer. It provided recommendations for clinical practice to improve early detection of metastatic disease. RADAR III focuses on updates regarding next generation imaging for improved guidance.
Important findings for imaging metastatic prostate cancer
In this video and associated slides, Dr Koo details the RADAR 1 and 3 recommendations, comparing conventional imaging to advanced PET imaging for detection of metastatic disease in prostate cancer. Prostate cancer PET detection rates as a function of PSA in patients with biochemical recurrence are addressed. The suitability of radiotracers for next generation imaging is discussed, and how to approach different patient groups. Lastly, what test to use based on availability, accounting for location and coverage by MEDICARE. View the video and slides provided as part of our educational resources and practical guidance for medical oncologists and urologists.
GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.
Other programmes of interest
28 min
Other programmes developed by Dr. Phillip Koo
Dr. Phillip Koo
Nuclear Medicine Physician
Banner MD Anderson Cancer Center
United States (US)
